iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin Inks Strategic Deal with Amman Pharma for Biosimilar Market Expansion in MENA Region

10 Nov 2023 , 02:11 PM

Lupin Limited collaborates with Amman Pharmaceuticals Industries for Ranibizumab biosimilar marketing in the Middle East and select territories. The partnership covers countries like Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries.

Ranibizumab is a biosimilar of Lucentis, used to manage neovascular age-related macular degeneration (AMD) and macular edema. The drug is administered through eye injection, inhibiting abnormal blood vessel growth and preventing retina damage.

Collaboration aims to enhance patient access to innovative healthcare solutions in the MENA region. Lupin’s Managing Director, Nilesh Gupta, emphasizes the goal of transforming patients’ lives in the MENA region.

Dr. Cyrus Karkaria, President of Biotechnology at Lupin, underscores the commitment to providing access to advanced biosimilars at affordable costs. Dr. Fadi Alatrash, General Manager of Amman Pharma, highlights the collaboration’s role in strengthening Lupin’s biosimilar portfolio and position in the Ophthalmology market.

Lupin reported a 3.77-fold YoY rise in consolidated net profit at Rs 489.6 crore for Q2 of the current financial year. North America sales for the quarter reached Rs 18,66.6 crore, contributing to 40.4% growth YoY and accounting for 38% of Lupin’s global sales.

For feedback and suggestions, write to us at editorial@iifl.com

 

Related Tags

  • GCC countries
  • Lupin
  • MENA Region
  • partnership
  • Saudi Arabia
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.